Clinical Commissioning Policy: Bortezomib for relapsed/refractory mantle cell lymphoma (all ages)

Document first published:
Page updated:
Topic:
,
Publication type:

This policy document outlines the arrangements for funding of Bortezomib for relapsed/refractory mantle cell lymphoma.

Document

Clinical Commissioning Policy: Bortezomib for relapsed/refractory mantle cell lymphoma (all ages)

Clinical Commissioning Policy: Bortezomib for relapsed/refractory mantle cell lymphoma (all ages)

  • PDF
  • 124 KB
  • 17 pages